Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer

Inclusion Criteria:

• Histologically or cytologically (Bethesda 5 or 6) confirmed pancreatic ductaladenocarcinoma.

• Resectable tumor according to Dutch Pancreatic Cancer Group criteria: no arterialcontact and venous contact with the superior mesenteric vein or portal vein of 90degrees or less

• No evidence for metastatic disease

• WHO performance status of 0 or 1

• Ability to undergo surgery and mFOLFIRINOX chemotherapy

• Leucocytes (WBC) ≥ 3.0 x 10^9/L

• Platelets ≥ 100 x 10^9/L

• Hemoglobin ≥ 6.0 mmol/l

• Renal function: eGFR ≥ 40 ml/min

• Age ≥ 18 years

• Written informed consent

Exclusion Criteria:

• Prior radiotherapy, chemotherapy, or surgery for pancreatic cancer.

• Prior chemotherapy precluding mFOLFIRINOX.

• Previous malignancy (excluding non-melanoma skin cancer, pancreatic neuroendocrinetumor (pNET) <2cm, and gastrointestinal stromal tumor (GIST) <2cm), unless noevidence of disease and diagnosed more than 3 years before diagnosis of pancreaticcancer, or with a life expectancy of more than 5 years from date of inclusion.

• Pregnancy or lactation.

• Serious concomitant systemic disorders that would compromise the safety of thepatient or his/her ability to complete the study, at the discretion of theinvestigator.